相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical pharmacology of nicotine: Implications for understanding, preventing, and treating tobacco addiction
N. L. Benowitz
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent
Man Ki Ho et al.
PHARMACOGENETICS AND GENOMICS (2008)
Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4α to the proximal promoter
Tania Onica et al.
MOLECULAR PHARMACOLOGY (2008)
Identification of novel CYP2A6*1B variants: The CYP2A6*1B allele is associated with faster in vivo nicotine metabolism
J. C. Mwenifumbo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population
A. Rossini et al.
CARCINOGENESIS (2007)
CYP2A13: Variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
Xiuling Zhang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Genetic variability in CYP2A6 and the pharmacokinetics of nicotine
Jill C. Mwenifiumbo et al.
PHARMACOGENOMICS (2007)
Human CYP2A6 is induced by estrogen via estrogen receptor
Eriko Higashi et al.
DRUG METABOLISM AND DISPOSITION (2007)
Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes
Federica Gemignani et al.
CARCINOGENESIS (2007)
A novel duplication type of CYP2A6 gene in African-American population
Tatsuki Fukami et al.
DRUG METABOLISM AND DISPOSITION (2007)
Etiological study of esophageal squamous cell carcinoma in an endemic region: a population-based case control study in Huaian, China
Zemin Wang et al.
BMC CANCER (2006)
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine
Neal L. Benowitz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-γ coactivator 1α
Masahiro Itoh et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A
T. Fukami et al.
PHARMACOGENOMICS JOURNAL (2006)
Cytochrorne P450 2A6 polymorphism in nasopharyngeal carcinoma
Danai Tiwawech et al.
CANCER LETTERS (2006)
CYP2A6 polymorphisms in Malays, Chinese and Indians
M. Nurfadhlina et al.
XENOBIOTICA (2006)
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy
V Malaiyandi et al.
MOLECULAR PSYCHIATRY (2006)
Determination of 14 polycyclic aromatic hydrocarbons in mainstream smoke from US brand and non-US brand cigarettes
YS Ding et al.
ENVIRONMENTAL SCIENCE & TECHNOLOGY (2006)
3′-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression
J Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro
A Rossini et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2006)
Levels of toxins in oral tobacco products in the UK
A McNeill et al.
TOBACCO CONTROL (2006)
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations
Miki Nakajima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism
LB von Weymarn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais
Sompop Peamkrasatam et al.
DRUG METABOLISM AND PHARMACOKINETICS (2006)
A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity
T Fukami et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Three haplotypes associated with CYP2A6 phenotypes in Caucasians
M Haberl et al.
PHARMACOGENETICS AND GENOMICS (2005)
Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes
SE Murphy et al.
DRUG METABOLISM AND DISPOSITION (2005)
Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma
J Mochizuki et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2005)
Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity
T Fukami et al.
DRUG METABOLISM AND DISPOSITION (2005)
Determination of carcinogenic tobacco-specific nitrosamines in mainstream smoke from US-brand and non-US-brand cigarettes from 14 countries
WJ Wu et al.
NICOTINE & TOBACCO RESEARCH (2005)
Metabolism and disposition kinetics of nicotine
J Hukkanen et al.
PHARMACOLOGICAL REVIEWS (2005)
Metabolism of nicotine and cotinine by human cytochrome P450 2A13
ZP Bao et al.
DRUG METABOLISM AND DISPOSITION (2005)
CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians
GM Vasconcelos et al.
PHARMACOGENOMICS JOURNAL (2005)
High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana
MA Gyamfi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort
N Gambier et al.
PHARMACOGENOMICS JOURNAL (2005)
Cytochrome P450 2A-catalyzed metabolic activation of structurally similar carcinogenic nitrosamines: N '-nitrosonornicotine enantiomers, N-nitrosopiperidine, and N-nitrosopyrrolidine
HL Wong et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2005)
Identification of deletion-junction site of CYP2A6*4B allele lacking entire coding region of CYP2A6 in Japanese
N Ariyoshi et al.
PHARMACOGENETICS (2004)
Regulation of the cytochrome P450 2A genes
T Su et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2004)
Genetically decreased CYP2A6 and the risk of tobacco dependence:: a prospective study of novice smokers
J O'Loughlin et al.
TOBACCO CONTROL (2004)
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers
M Fujieda et al.
CARCINOGENESIS (2004)
A novel polymorphism of human CYP2A6 gene CTP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo
T Fukami et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6)
O von Richter et al.
PHARMACOGENETICS (2004)
A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity
M Pitarque et al.
HUMAN MUTATION (2004)
Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13
JR Jalas et al.
DRUG METABOLISM AND DISPOSITION (2003)
Tobacco carcinogens, their biomarkers and tobacco-induced cancer
SS Hecht
NATURE REVIEWS CANCER (2003)
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro
R Yoshida et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Decreasing smoking behaviour and risk through CYP2A6 inhibition
EM Sellers et al.
DRUG DISCOVERY TODAY (2003)
CYP2A6 genetic variation and potential consequences
C Xu et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism
R Yoshida et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity
M Oscarson et al.
HUMAN MUTATION (2002)
Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma
H Tsukino et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur
S Daigo et al.
PHARMACOGENETICS (2002)
CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka
Z Topcu et al.
CARCINOGENESIS (2002)
CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism
W Godoy et al.
CARCINOGENESIS (2002)
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles
C Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method
T Paschke et al.
TOXICOLOGY (2001)
Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19
SMG Hoffman et al.
PHARMACOGENETICS (2001)
Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis
C Heeschen et al.
NATURE MEDICINE (2001)
Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene:: Impairment of its promoter activity
M Pitarque et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Nicotine metabolism and CYP2A6 allele frequencies in Koreans
JT Kwon et al.
PHARMACOGENETICS (2001)
CYP2A6*6, a novel polymorphism in cytochrome P450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity
K Kitagawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A novel single nucleotide polymorphism altering stability and activity of CYP2A6
N Ariyoshi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population
MA Loriot et al.
PHARMACOGENETICS (2001)
Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans
M Nakajima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C
N Ariyoshi et al.
PHARMACOGENETICS (2000)
Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking
EM Sellers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Genetic polymorphism of CYP2A6 in the German population
M Bourian et al.
TOXICOLOGY (2000)
分享论文
